Who
Cyrus Harmon
Director
Company insider
Files Form 4 as: Chief Research Officer, Olema Pharmaceuticals.
In numbers
- Trades disclosed
- 71
- Buys
- 0
- Sells
- 43
- Bought
- $0
- Sold
- $7.2M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 15 Jun 2020
- Last trade
- 24 Jul 2026
- Last filed
- 27 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Jul 2026filed 27 Jul 2026 | OLMA Olema PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $146K12,500 at $11.71 | filing |
| 24 Jul 2026filed 27 Jul 2026 | OLMA Olema PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $146K12,500 at $11.71 | filing |
| 23 Jul 2026filed 27 Jul 2026 | OLMA Olema PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $145K12,500 at $11.58 | filing |
| 23 Jul 2026filed 27 Jul 2026 | OLMA Olema PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $145K12,500 at $11.58 | filing |
| 18 Jun 2026filed 23 Jun 2026 | OLMA Olema Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,500 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | OLMA Olema Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,500 at $0.00 | filing |
| 20 Jan 2026filed 21 Jan 2026 | OLMA Olema PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $269K10,000 at $26.88 | filing |
| 20 Jan 2026filed 21 Jan 2026 | OLMA Olema PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $269K10,000 at $26.88 | filing |
| 14 Jan 2026filed 16 Jan 2026 | OLMA Olema PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $102K3,489 at $29.12 | filing |
| 14 Jan 2026filed 16 Jan 2026 | OLMA Olema PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $102K3,489 at $29.12 | filing |
| 22 Dec 2025filed 29 Dec 2025 | OLMA Olema PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $82K2,881 at $28.53 | filing |
| 18 Sep 2025filed 18 Sep 2025 | OLMA Olema PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $83K10,000 at $8.33 | filing |
| 18 Sep 2025filed 18 Sep 2025 | OLMA Olema PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $26K3,086 at $8.32 | filing |
| 16 Sep 2025filed 18 Sep 2025 | OLMA Olema PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $80K10,000 at $8.04 | filing |
| 16 Sep 2025filed 18 Sep 2025 | OLMA Olema PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $15K1,914 at $8.08 | filing |
| 11 Jun 2025filed 13 Jun 2025 | OLMA Olema Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,150 at $0.00 | filing |
| 11 Dec 2024filed 11 Dec 2024 | OLMA Olema PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $69K7,958 at $8.66 | filing |
| 11 Dec 2024filed 11 Dec 2024 | OLMA Olema PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1,681179 at $9.39 | filing |
| 10 Dec 2024filed 11 Dec 2024 | OLMA Olema PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $77K8,256 at $9.37 | filing |
| 9 Dec 2024filed 11 Dec 2024 | OLMA Olema PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —29,250 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.